Drug Trial Radar · NCT06989645
A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Aug 19, 2025
Primary completion
Feb 2, 2026
Study completion Mar 2, 2026
Sponsor
- Lead sponsor
- Synartro ABIndustry
- Sponsor type
- Industry
- Collaborators
- CTC Clinical Trial Consultants AB
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a, phase 1/2a trial, to assess the safety, tolerability, systemic exposure as well as preliminary efficacy following a single intra-articular injection of 3 dose levels of SYN321 in patients with symptomatic knee osteoarthritis (KOA).
Conditions
- Osteoarthritis of Knee
Interventions
SYN321Drug
Intra-articular
PlaceboDrug
Intra-articular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and intensity of adverse eventsTime frame: From IMP injection (day 1) until end of trial visit (day 56)
- Clinically significant changes in ECGTime frame: From screening until end of trial visit (day 56)
- Clinically significant changes in blood pressureTime frame: From screening until end of trial visit (day 56)
- Clinically significant changes in heart rateTime frame: From screening until end of trial visit (day 56)
- Clinically significant changes in body temperatureTime frame: From screening until end of trial visit (day 56)
- Clinically significant changes in Clinical Laboratory ProfileTime frame: From screening until end of trial visit (day 56)
- Clinically significant changes in urine analysisTime frame: From screening until end of trial visit (day 56)
- Clinically significant changes in Physical ExaminationTime frame: From screening until end of trial visit (day 56)
- Clinically significant changes of local tolerability reactionsTime frame: From screening until end of trial visit (day 56)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cinical Trial Consultants AB
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.